Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden
Authors:
- C. ThomasCTC. Thomas
- J. BeckJBJ. Beck
- C. HampelCHC. Hampel
- C. KriegerCKC. Krieger
- P. E. BaquéPBP. E. Baqué
- A. HelischAHA. Helisch
- M. SchreckenbergerMSM. Schreckenberger
- M. MiedererMMM. Miederer
- 1 September 2015
- journal article
- clinical trial
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 54 (05) , 197-203
Abstract
Summary: In patients with metastasized, castration resistant prostate cancer (mCRPC) treatment with radium-223 (Xofigo) is an attractive therapeutic option. In particular, patients with high tumour load seem to profit from this treatment in regard of survival and quality of live. Aim of this study was to stratify mCRPC patients according to a quantitative imaging marker derived from routine bone scans (EXINI bone) and analyze haematopoietic toxicity of Xofigo in these patients. Patients, methods: Toxicity and oncologic outcome were investigated in a cohort of 14 patients with high tumour load. Additionally, based on a web survey, experience of toxicity in 41 high tumour load patients in Germany in 2014 was collected. Results: In patients with a bone scan index (BSI) greater than 5, significant toxicity occurred in more patients than expected from the ALSYMPCA trial. This was associated with application of fewer cycles. Similar experiences have been made in other centers in Germany. Approximately 7% of these patients will need very long time or will not recover from grade ≥ 3 toxicity. Conclusion: Close follow-up of haematopoietic indices and, in case of toxicity, early termination of therapy is in particular necessary in late stage disease where limited bone marrow reserve is likely.Keywords
This publication has 9 references indexed in Scilit:
- Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall SurvivalJournal of Nuclear Medicine, 2015
- Radium-223 in the Treatment of Osteoblastic Metastases: A Critical Clinical ReviewInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastasesAnnals of Nuclear Medicine, 2013
- Dosimetry of 223Ra-chloride: dose to normal organs and tissuesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan IndexEuropean Urology, 2012
- Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonateSeminars in Nuclear Medicine, 2001
- Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- A dose-controlled study of 153Sm-Ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastaseEuropean Journal of Cancer, 1997